Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency

Background: Data regarding the course of SARS-CoV-2 infection in children with primary immunodeficiency (PID) is insufficient. The purpose of the study was to evaluate the morbidity and clinical course of COVID-19 and the ability to produce anti-SARS-CoV-2 IgG antibodies in children with PID. Method...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karolina Pieniawska-Śmiech, Anna Kuraszewicz, Joanna Sado, Karol Śmiech, Aleksandra Lewandowicz-Uszyńska
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	anti-SARS-CoV-2 antibodies COVID-19 primary immunodeficiency SARS-CoV-2 PIMS-TS Medicine R
Acceso en línea:	https://doaj.org/article/4108c7e06e3f4137bfa734158fc7e351
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4108c7e06e3f4137bfa734158fc7e351
record_format	dspace
spelling	oai:doaj.org-article:4108c7e06e3f4137bfa734158fc7e3512021-11-11T17:43:51ZAssessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency10.3390/jcm102151112077-0383https://doaj.org/article/4108c7e06e3f4137bfa734158fc7e3512021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5111https://doaj.org/toc/2077-0383Background: Data regarding the course of SARS-CoV-2 infection in children with primary immunodeficiency (PID) is insufficient. The purpose of the study was to evaluate the morbidity and clinical course of COVID-19 and the ability to produce anti-SARS-CoV-2 IgG antibodies in children with PID. Methods: In this retrospective study, medical records of 99 patients aged 0–18 were evaluated. The patients were divided into three groups: PID group (68.69%), control group (19.19%) and patients with ongoing or previous paediatric inflammatory multisystem syndrome (12.12%). Data such as morbidity, clinical outcome, and IgG anti-SARS-CoV-2 antibody titres were assessed. Results: A confirmed diagnosis of SARS-CoV-2 infection has been established in 26.47% of patients with PID. Among patients with PID infected with SARS-CoV-2, only three cases were hospitalised. Mortality in the PID group was 0%. Throughout an observation period of 1 year, 47.06% of patients with PID were tested positive for the anti-SARS-CoV-2 antibody. Conclusions: In the study group, in most cases the disease had a mild and self-limiting course. Remarkably, even though IgG deficiency was the most prevalent form of PID in the study group, the patients were able to respond satisfactorily to the infection in terms of anti-SARS-CoV-2 IgG.Karolina Pieniawska-ŚmiechAnna KuraszewiczJoanna SadoKarol ŚmiechAleksandra Lewandowicz-UszyńskaMDPI AGarticleanti-SARS-CoV-2 antibodiesCOVID-19primary immunodeficiencySARS-CoV-2PIMS-TSMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5111, p 5111 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-SARS-CoV-2 antibodies COVID-19 primary immunodeficiency SARS-CoV-2 PIMS-TS Medicine R
spellingShingle	anti-SARS-CoV-2 antibodies COVID-19 primary immunodeficiency SARS-CoV-2 PIMS-TS Medicine R Karolina Pieniawska-Śmiech Anna Kuraszewicz Joanna Sado Karol Śmiech Aleksandra Lewandowicz-Uszyńska Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
description	Background: Data regarding the course of SARS-CoV-2 infection in children with primary immunodeficiency (PID) is insufficient. The purpose of the study was to evaluate the morbidity and clinical course of COVID-19 and the ability to produce anti-SARS-CoV-2 IgG antibodies in children with PID. Methods: In this retrospective study, medical records of 99 patients aged 0–18 were evaluated. The patients were divided into three groups: PID group (68.69%), control group (19.19%) and patients with ongoing or previous paediatric inflammatory multisystem syndrome (12.12%). Data such as morbidity, clinical outcome, and IgG anti-SARS-CoV-2 antibody titres were assessed. Results: A confirmed diagnosis of SARS-CoV-2 infection has been established in 26.47% of patients with PID. Among patients with PID infected with SARS-CoV-2, only three cases were hospitalised. Mortality in the PID group was 0%. Throughout an observation period of 1 year, 47.06% of patients with PID were tested positive for the anti-SARS-CoV-2 antibody. Conclusions: In the study group, in most cases the disease had a mild and self-limiting course. Remarkably, even though IgG deficiency was the most prevalent form of PID in the study group, the patients were able to respond satisfactorily to the infection in terms of anti-SARS-CoV-2 IgG.
format	article
author	Karolina Pieniawska-Śmiech Anna Kuraszewicz Joanna Sado Karol Śmiech Aleksandra Lewandowicz-Uszyńska
author_facet	Karolina Pieniawska-Śmiech Anna Kuraszewicz Joanna Sado Karol Śmiech Aleksandra Lewandowicz-Uszyńska
author_sort	Karolina Pieniawska-Śmiech
title	Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_short	Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_full	Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_fullStr	Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_full_unstemmed	Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_sort	assessment of covid-19 incidence and the ability to synthesise anti-sars-cov-2 antibodies of paediatric patients with primary immunodeficiency
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4108c7e06e3f4137bfa734158fc7e351
work_keys_str_mv	AT karolinapieniawskasmiech assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency AT annakuraszewicz assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency AT joannasado assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency AT karolsmiech assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency AT aleksandralewandowiczuszynska assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency
_version_	1718431997085351936

Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency

Ejemplares similares